Yancheng Yu

11PUBLICATIONS

9CO-AUTHORS

Medical infection agents (incl. prions)Molecular targetsBiomolecular modelling and designBioinformatic methods developmentBiologically active molecules

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (11)

Sort by Publication Date:

|May 23, 2026

Discovery of FYJ-195 as a Highly Potent FLT3 Inhibitor against Multiple Acquired Resistance Mutations in Acute Myeloid Leukemia.

|May 02, 2026

Discovery of <b>CN-3</b> as a Next-Generation RET Inhibitor Potently Overcoming Multiple Mutations.

|Apr 03, 2026

Discovery of FLC-8 as the First Covalent FLT3 Inhibitor Targeting Cys807 for FLT3 Mutant Acute Myeloid Leukemia.

Zi-Xuan Wang, Xiao-Long Jing, Qian Liu

|Dec 26, 2024

Design, Synthesis, and Biological Evaluation of 3,4-Dihydroisoquinolin-1(<i>2H</i>)-one Derivatives as Protein Arginine Methyltransferase 5 Inhibitors for the Treatment of Non-Hodgkin's Lymphoma.

Qing-Qing Li, Xu Quan, Zi-Xuan Wang

|Dec 02, 2024

Kinase-Bench: Comprehensive Benchmarking Tools and Guidance for Achieving Selectivity in Kinase Drug Discovery.

Tian-Hua Wei, Shuang-Shuang Zhou, Xiao-Long Jing

|Nov 15, 2024

Discovery of 1-(Phenylsulfonyl)-1,2,3,4-tetrahydroquinoline Derivative as Orally Bioavailable and Safe RORγt Inverse Agonists for Potential Treatment of Rheumatoid Arthritis.

Shan-Liang Sun, Hong-Jiang Xu, Xiao-Long Jiang

Pageof 2

Frequent Collaborators

Nian-Guang Li

Xin Xue

Xiao-Long Wang

Peng Cao

Jian Liu

Zi-Xuan Wang

Zhang Zhang

Zhimou Guo

Xinmiao Liang

Frequent Collaborators

Nian-Guang Li

Xin Xue

Xiao-Long Wang

Peng Cao